The most comprehensive pipeline review Dravet Syndrome - Drug
Development Pipeline Study provides in-depth analysis and update
information on Dravet Syndrome pipeline drugs. Current status of all the
drugs in the Dravet Syndrome pipeline is provided in the research work.

Previously known as severe myoclonic epilepsy of infancy (SMEI), the
neurological disease is attracting wide interest from pharmaceutical
companies over the past five years. In particular, with 10 drugs
receiving orphan drug status, the prominence of Dravet Syndrome pipeline
is robust.

The report provides detailed analysis of Dravet Syndrome pipeline
including companies involved, drugs in different stages of development,
drug development details across regions (North America, Europe, Asia
Pacific and Rest of the World). Furthermore, the Dravet Syndrome report
identifies aspects important in modifying industry market scenarios,
increasing opportunities and list of potential companies that impact the
Dravet Syndrome industry.

Scope:

All latest industry developments and their impact on projects and
companies